





A**B****C****D**

Supplemental Fig. S2 | Differences in transcript and protein expression levels between A375 parental and resistant cells. **A)** Differentially expressed (DE) genes between 451Lu parental and resistant cells were analyzed, including several genes in the MAPK pathway, suggesting that BRAFi resistance may be mediated in part through reactivation of alternate MAPK pathway genes. **B)** Drug sensitivity was measured through the use of MTT assays to assess metabolically active A375-Par and A375-BR cells 48 hours following BRAFi application. **C)** Differentially expressed genes between A375 parental and resistant cells were analyzed, including several genes in the MAPK pathway, suggesting the BRAFi resistance may be mediated in part through reactivation of alternate MAPK pathway genes. Of note, these genes show little overlap with the significantly DE genes in the MAPK pathway identified for 451Lu cell lines in panel **A** above (the exceptions are JUN, EGFR, and COL1A1). **D)** Heatmaps showing all genes significantly differentially expressed in either A375 or 451Lu derived cell lines suggests there is minimal overlap in genes up-regulated in A375 BRAFi resistant cells as compared to those up-regulated in 451Lu BRAFi resistant cells.